INNOGEN
Latest round
- Series B
Last raised
- Jan 2024
Total raised
- $155M
Investors
- 18
About INNOGEN
, trading as INNOGEN, is an international pharmaceutical manufacturing and R&D company. The long-acting human-sourced GLP-1 drug passed the CDE clinical approval in May 2018.68 per share on the Hong Kong Stock Exchange under the ticker symbol "2591". The company's product Diabigone is long-acting hypoglycemic Supaglutide injection for type 2 diabetes. It is currently undergoing clinical trials. The company's other pipeline research projects are original drugs for type 1 and type 2 diabetes, obesity, and diabetic complications. In addition to recombinant protein biopharmaceuticals, chemical products are also included in nearly ten pipeline products. One of the small molecule compounds has completed a clinical phase 1 study. The company generates revenue through the research and development of medicines for diabetes and other metabolic diseases. The company plans to ongoing the planned commercialization of its core product and expansion of the Group's internal sales and marketing team.
Who invested in INNOGEN
18 investors across 3 rounds
See all investors in INNOGEN
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about INNOGEN
Who invested in INNOGEN?
INNOGEN has 18 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has INNOGEN raised?
INNOGEN has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did INNOGEN last raise money?
INNOGEN's most recent round on record is a Series B, in Jan 2024.
What does INNOGEN do?
, trading as INNOGEN, is an international pharmaceutical manufacturing and R&D company.
Where is INNOGEN headquartered?
INNOGEN is headquartered in Shanghai, China.
Which VCs invest in companies like INNOGEN?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at INNOGEN's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like INNOGEN? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.